A Form 4 filed on August 6, 2026 discloses that Anterix Inc. director Mark Fleischhauer acquired 1,598 shares of common stock on August 4, 2026 at a price of $0, bringing his total direct beneficial ownership to 14,367 shares.

Key Highlights

  • Acquisition date: The transaction was recorded on August 4, 2026.
  • Shares acquired: 1,598 shares of Anterix common stock were acquired (transaction code A) at a price of $0.
  • Post-transaction ownership: Fleischhauer directly beneficially owns 14,367 shares following the reported transaction.
  • Restricted stock vesting: According to the filing, the shares "will vest on the earlier of the 2027 Annual Meeting of shareholders and August 4, 2027, subject to the terms of the Restricted Stock Agreement."
  • Reporting person role: Fleischhauer is identified as a Director of Anterix Inc. (NASDAQ: ATEX).
  • Filing agent: The form was signed by Gena L. Ashe as Attorney-in-Fact on August 6, 2026.

Anterix Director Mark Fleischhauer Reports Restricted Stock Grant

According to the Form 4 filed with the SEC, Mark Fleischhauer, a director of Anterix Inc., received 1,598 shares of the company's common stock on August 4, 2026. The transaction was coded "A" (acquired) and carried a price of $0, consistent with a restricted stock award rather than an open-market purchase. The filing identifies the issuer as Anterix Inc., trading on NASDAQ under the ticker ATEX.

The filing notes in its explanation of responses that the shares are subject to vesting conditions: they "will vest on the earlier of the 2027 Annual Meeting of shareholders and August 4, 2027, subject to the terms of the Restricted Stock Agreement." No derivative securities transactions were reported in Table II of the form.

Following the reported transaction, Fleischhauer's direct beneficial ownership stands at 14,367 shares of Anterix common stock, according to the filing. The form was filed by one reporting person and was signed by Gena L. Ashe as Attorney-in-Fact on August 6, 2026. No amendment date was indicated, suggesting this is an original filing.

What Was Disclosed

The filing reports a single acquisition of 1,598 restricted shares of Anterix common stock by director Mark Fleischhauer on August 4, 2026, at no cost. Post-transaction, he directly holds 14,367 shares, with the new shares subject to a vesting schedule tied to the 2027 Annual Meeting or August 4, 2027.